Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Oriola-KD Oyj, Q2'24

By Inderes7/18/2024, 7:00 AM
Oriola

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:01 - 01:02

Good morning everyone, and a warm welcome to Oriola's Q2 results webcast. I am pleased to host a new spokesperson from Oriola's Investor Relations with me today. We have our CEO, Katerina Gabrielson, and our CFO. Good morning. After the presentation, we will open up for your questions, and you can start posting them to us already during the presentation. As a reminder, in the Q&A, we will focus on questions relating to Oriola's business and financial development. We can and will answer questions on Kronans upper deck, but only within a limited scope. Finally, please note that we are also recording this webcast, and the recording will be available on our website later today. Before handing over to Catharina. Katarina, here is the customary disclaimer that we all should be aware of. And now, without further ado, Katarina, please go ahead.

Katarina Gabrielson
01:02 - 07:55

Thank you. Good morning and welcome also on my behalf. We'll start today with the quarter two highlights and a couple of comments on the operating environment and markets. And then I'll end my part with a review of the segments. After this, Timur will take you through the financials before we continue with the question and answer session. In quarter two, we saw good top-line growth, with net sales growing by 13% to €440 million. This was driven by both distribution and wholesale segments. Profitability improved in quarter two. Adjusted EBIT improved by 53% to €5.1 million, while the adjusted EBIT excluding the Swedish dose dispensing business, was €4.9 million. The improvement in profitability was supported by net sales growth, lower operating expenses, and freight costs. We are implementing and rolling out our refined strategy, which was launched at the end of last year. The ERP and warehouse management investment that was kicked off in January has progressed according to plan. At the moment, we are reaching the end of the design phase, which will allow us to move into the build phase during the second half of this year. Something that I have personally also focused quite a lot on during this quarter is engaging with our employees and discussing the strategy and what it means in different parts of the organization. These discussions have been fruitful and, in my opinion, extremely important for creating alignment and commitment to our long-term goals. That is something that we will continue to do. And then finally, a couple of comments on the joint venture company Kronans. Apotekstjänst Sverige AB in quarter two. E-commerce continued to grow steadily, while the brick-and-mortar sector is stabilizing. Kronans Apotek got a new CEO in April and the CFO in May, and they have implemented new measures to improve performance. At the end of April, we announced that the Swedish Competition Authority has prohibited the sale of Svensk dos AB products or services to our protective suites, due to negative effects on market competition. We still think the agreement with Apotekstjänst Sverige AB makes sense and is the most viable option for Oriola, because we have not seen any changes in the market structure and dynamics. We believe that the decision taken by the authorities was not justified and that it was based on weak argumentation. This is why we, together with Apotekstjänst Sverige AB, have appealed the decision. The appeal process can take up to six months, so there will not be news about other alternatives before we have a clear ruling on this. And that will be sometime in early quarter four. If we take a look at the overall operating environment, we can see that the situation has clearly stabilized from a year back. Consumer confidence has slightly improved, cost inflation has slowed down, and we can see that the energy and fuel prices have stabilized. In the pharmaceutical market environment, there are continuing availability issues across the whole of Europe. We can also see that the demand for high-value pharmaceuticals is at a good level, and this is boosting the value growth in the pharmaceuticals market. On the other hand, volumes, especially in the finished market, have declined, while in Sweden the volume was still growing at the low single-digit level. As said, the pharmaceutical distribution market's value has continued on a good solid growth in quarter two, which grew about 7% in Sweden and 4% in Finland. In the Finnish market, our market share in quarter two was stable year on year at 45%, and in Sweden we saw a slight decline from 45 to 43%. In the Finnish dose dispensing business, our market share increased by two percentage points to 30%. On this page, you can also see the data from the consumer health market. This is annual data and we will comment on it only on an annual basis. But as you can see, the historical growth has been at 3% and the market is valued at around €1.5 billion. Let's start then turn and look at how we performed in quarter two. I'll start with the distribution segment, which consists of pharmaceutical logistics and dose dispensing services. In quarter two, net sales grew by 16% to €358 million. This was largely driven by the steady market value growth in Sweden and Finland. Profitability improved to 30%, with adjusted EBIT increasing to €4.4 million. Profitability improvement was supported by net sales growth and a lower cost base, which has offset the negative impact due to lower volumes in the move and a move of clinical trials under the management of advisory services in wholesale segments. Freight costs were lower thanks to operational improvements, and lower fuel prices, and operating expenses were lower due to cost reductions in the Swedish dose dispensing business. When we exclude the Swedish dose dispensing business, adjusted EBIT was €3.8 million, slightly below last year due to the decline in volume and the move of clinical trials within the EU in the distribution business. We will continue to build on the good development we saw last year in quarter two. We have been successful in renewing distribution agreements and implementing price increases, which will have a positive impact in the second half. Then, when we're looking at the wholesale segment, the whole segment consists of wholesale of traded goods and over-the-counter or OTC products, parallel import and special licensed medicines, as well as advisory services. In quarter two, net sales in this segment grew by 3% to €82 million, supported by a wider product portfolio in Sweden and growth in all customer segments. Profitability improved to €2.3 million. This is mainly related to the move of clinical trials which I mentioned earlier. Growing the wholesale business is one of our long-term strategic goals. During the start of this year, our focus has been on building our offering and capabilities. For example, we want to grow in the growing e-commerce channel in Sweden, and this has required us to develop certain capabilities in the warehouse in Sweden. This concludes my part. So, over to you, Timo, for the financials.

Timo
07:59 - 16:39

Thank you, Katarina, and good morning from me as well. Let's first recap how we have performed in comparison to previous years. We can see good growth in top-line revenue. Invoicing grew by 5% to €952 million, and net sales grew by 13% to €439 million. Solid growth, which we can be pleased about. Adjusted EBIT increased from €3.4 million to €5.1 million. An increase of 53%. And when we exclude the Swedish dose dispensing business, we see that the adjusted EBIT increased by 18% to €4.9 million. Let's then look at the net sales and EBIT breakdowns. The growth is largely driven by the distribution segment, where growth was €49 million. In the wholesale segment, net sales grew by €2.3 million. Group items on net sales were not significant, while the Swedish dose dispensing business contributed positively to net sales by roughly €3 million. This gives a total of €439 million in net sales on the EBIT side. The chart shows that the development, excluding Swedish dose, where the EBIT in Q2 increases to €4.9 million in the distribution segment. EBIT excluding Swedish dose, declined slightly in the distribution segment, while wholesale also saw some improvement. The decline in distribution is due to the decline in volumes and the move of clinical trials under the management or advisory services in the wholesale segment. This explains the positive development in wholesale segments as well. To summarize, in Q2, EBIT excluding Swedish dose was at €4.9 million and with the small positive contribution from Swedish dose, adjusted EBIT comes to €5.1 million compared to €3.4 million in Q2 last year. Overall profitability improvement was supported by the net sales growth, lower operating expenses, and freight costs. Then moving on to the profit for the period. In Q2, profit for the period was €2 million and earnings per share were €0.01. We had adjusted items of €0.5 million positive in Q2. These were related to the dose dispensing business and the ERP implementation. Costs, which in Q2 amounted to €0.6 million in the dose dispensing business, were offset by a compensation of €1.4 million from the Court of Appeal regarding the tender process, and we had costs of €0.2 million relating to the sale of the dose dispensing business in Sweden in Q2. We recognized a loss of €1.3 million from Kronans Apotek, compared to a profit of €0.2 million in Q2 last year. On the net financial expenses, we can see the positive impact of lower debt levels as the net financial expenses decreased to €1.6 million compared to €1.9 million last year. Thus there was an improvement in profit for the period compared to Q2 last year. Then, examining the cash flow. Net cash flow from operating activities in Q2 was €17.8 million. These changes in the net working capital accounted for €11.5 million. It is typical for our industry that working capital fluctuates from quarter to quarter, as seen in Q2. Increases in trade payables have positively impacted working capital. When we examine the changes in the cash flow from the year-end, net cash flow from operating activities was €6.5 million, from investing activities, -€1.5 million, and from financing activities, -€57.2 million. The change in cash flow from financing activities reflects repayments of debt and includes a dividend payment of €12.7 million. All in all, the cash position is strong, with cash and cash equivalents amounting to €86 million at the end of the period. Like you saw in the cash flow, we lowered our debt level significantly compared to the previous year in Q2. We have repaid our term loans of 290 million Swedish crowns and issued fewer commercial papers, and the amount of lease liabilities has also decreased year-on-year. Following this, our interest-bearing debt was down €63 million from Q2 last year. At the end of the period, our interest-bearing debt amounted to €74 million, compared to €137 million at the end of Q2 last year. Cash and cash equivalents amounted to 86 million. This results in a net depreciation and clearing of -8.1%. The amount of short-term receivables at the end of the period was 55 million, which is lower than in the previous year due to the timing effect. And this, of course, also affects our cash position. To summarize, I want to say that we continue to have a strong financial position with good cash flow and, erring on the negative side. Equity ratio has declined from 22.2% to 17.2%, but it is stable compared to the previous quarters. Then we will shortly move on to comment on Corona's impact. In Corona, e-commerce has continued to demonstrate steady growth, while the brick-and-mortar sector has stabilized. As Caterina mentioned, the company has grown and has both a new CEO and CFO who have already implemented new measures to improve the business. In Q2, adjusted EBIT declined from €2.3 million to €0.3 million. The results are still not satisfactory. We see that there is a significant improvement from Q1 to Q2. Realized net sales from Corona support exports amounted to €0.9 million, and one-off costs relating to the integrations totaled €1.9 million for Q2. We have recognized a loss of €1.3 million in our balance sheet from Kronans Apotek, and just to notify that Kronans Apotek remains an important strategic partner for Oriola Corporation, and we will actively support Kronans Apotek. Apotekstjänst Sverige AB value creation as a major shareholder. Kronans Apotek expects its full profit potential to materialize by the end of 2025. Our guidance or outlook for 2024 remains unchanged. We expect the Adjusted EBIT, excluding the dose dispensing business in Sweden, for the year 2024 to increase from the Adjusted EBIT for 2023, which was €19.5 million. As key assumptions, we expect the pharmaceutical distribution market to continue to grow. However, the continuation of weak consumer confidence might impact the wholesale market development. Additionally, the inflationary environment and related cost pressures may impact profitability. With this, I'm ready to hand back over to Katarina. Yes.

Katarina Gabrielson
16:41 - 17:15

Thank you, Timo. Before we take your questions, I want to summarize with three key takeaways that you can also see on this picture. Net sales grew year on year with positive development in both segments. And I'm really, really pleased about that. When looking at the profitability of the underlying business, we can see a solid improvement from the previous year. And last but not least, we have a solid financial position and have strengthened the balance sheet by significantly reducing our interest-bearing debt. With this, let's see if there are some questions.

Unknown 1
17:17 - 18:03

Great. Thank you both, Katarina and Dima, for the presentation. So let's have the questions. And just to remind everyone, you can post the questions to us through the chat in the webcast. So we have a question about the distribution segment. Net sales in the distribution segment grew by over 15%. And this was commented as being driven by value growth in the market, both in Sweden and Finland. However, market growths are presented as 7% and 3.8%, while market share is not growing. What is behind Oriola Corporation's outperformance of the market? Have there been any changes within the product portfolio? Compared to last year?

Timo
18:05 - 18:45

Yes, I can say. Yeah. So basically thinking about the market in general. So there are always differences in which types of medicines are sold more or less. It appears that the portfolio we currently have has been performing strongly during Q2, but ultimately, there are no significant changes in the market in that regard, although it fluctuates a bit from quarter to quarter.

Unknown 1
18:47 - 18:59

Okay, good. And then we have a question about the ERP costs. Why do you now treat ERP costs as adjusting items? Timo, please go ahead.

Timo
18:59 - 19:33

Yeah. Just to provide clarity to our reporting and information that we are giving to the market. Because we have those costs that actually yield positive benefits only after several years. It's very difficult to determine how our underlying business is developing if we have those costs embedded in everything. And basically that's why we decided that we want to have them or report them separately.

Unknown 1
19:34 - 19:50

All right. So, according to the latest news and court decision, you don't have the right to appeal. Uh, would you like to comment on this? I can.

Katarina Gabrielson
19:50 - 20:24

No, we don't have the right to appeal. But of course, we are behind our projections or best appeal, and we are fully supporting that. Like I said also in the presentation, we think that this is not a justified decision that was made by the Canadian circuit. And we really think that there is strong argumentation in this appeal. And that also means, of course, that we will then not comment further on what we will do if this deal does not go through until the verdict has been delivered.

Unknown 1
20:26 - 20:40

We continue in English, so maybe this is more for Timo to comment. So what kind of earnings should we expect from Swiss doors stores in the second half? Some losses or around breakeven like in Q2?

Timo
20:40 - 20:55

Well, that's just one thing that we are not going to comment on because at the end of the day, we are commenting on the profitability of the entire group, and it's one part of the group, but unfortunately, no comments on that one.

Katarina Gabrielson
20:55 - 21:11

I think it's fair to say, from this team's perspective, that we are supporting the business. And of course, we are having the same volumes. So, we can comment. We don't see any changes in customers and so on. Yes.

Unknown 1
21:12 - 21:19

Okay. Good. So then, what were the main reasons behind your low cash flow in the second quarter?

Timo
21:20 - 21:43

Uh, mainly kind of repayment of the loans. And that has been intentional. In previous quarters, I mentioned that we especially want to focus on this now, given the high interest rates. So our interest-bearing debt position is down. And I think that we have succeeded quite well on that one.

Unknown 1
21:45 - 22:11

All right. So we have a couple more questions. But just to remind everyone, please send them through the chat so that we can address them today. Um, but the next question is about the increase in number of personnel. The increase, which was quite high during Q2, was notable. So why is that? And is there a risk of an increase in operating expenses?

Katarina Gabrielson
22:12 - 22:40

I can address that question. You can say that what we are now doing is also looking at the wholesale segment. And during the first half, we have strengthened the wholesale segment. This is part of the strategic work. Accordingly, we can see a slight decrease in the number of personnel. We are not expecting this increase to continue in this aspect, as most of the required tasks have now been completed, at least to the extent that we can foresee at this point.

Unknown 1
22:41 - 22:49

All right. And then the last question, why didn't the good sales growth demonstrate an increase in your profitability, Tomas?

Timo
22:50 - 23:38

Well, there are essentially two factors, as stated in our release. The value of the sales is one thing. There are inflation and price increases, and on the other hand, there are volumes. We have two types of agreements: transaction-based and those based on other factors. When dealing with transaction-based agreements, It doesn't fully translate into profitability and sales margins. But of course, as we see volumes starting to increase, This will also positively affect our profitability.

Unknown 1
23:40 - 24:10

All right. Thank you. There are no more questions in the chat. Let's thank everyone for joining us today and remind you that our next webcast will take place on the 30th of October when we publish the Q3 report. Until then, if you have any questions, please don't hesitate to reach out to us. I would like to wish everyone a very pleasant summer. Thank you.

Unknown 2
24:10 - 24:11

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…